Cannabis Business

October 27, 2026

Grön is accelerating its nationwide footprint with today's announcement that the cannabis edibles brand has officially launched its Pearls product line in Massachusetts, New Mexico and Washington, marking the third major expansion wave in 2026. The move follows the company's entry into four additional states in early September and comes on the heels of what the company calls its largest-ever Halloween limited-edition release—the tarot-themed Grön Arcana, which outsold any previous Grön LTO in company history. Money Since parent company Wyld acquired Grön in December 2025, the brand has leveraged its parent's production-to-distribution model to fuel exponential sales growth and market penetration across previously untapped regions. The Pearls line, which differentiates itself through innovative THC-to-cannabinoid ratios including CBC, CBD, CBG and CBN, will hit dispensary shelves immediately across all three states.

Meanwhile, the global medical cannabis market is on track for transformative growth, with projections from The Business Research Company showing the industry reaching $106.5 billion by 2030—more than doubling from the current $39.52 billion in 2025. Notable The forecasted 22% compound annual growth rate through 2030 is being driven by expanding medical legalization, growing patient demand, increased scientific research, and improvements in extraction and formulation technologies. North America currently holds the largest share of the global market, while the Asia-Pacific region is projected to experience the fastest growth in the coming years. The market analysis identifies major operators including Curaleaf, Trulieve, Green Thumb Industries, Cresco Labs, Tilray, Canopy Growth, and Aurora Cannabis as key players in this expanding sector.

Puerto Rico—home to more than 250 active cannabis dispensaries and $180 million to $240 million in annual medical cannabis sales—is positioning itself as Latin America's dominant legal cannabis market. The island will host its first High Times Medical Cannabis Cup on December 5 in Old San Juan, featuring performances by Farruko, Jon Z, and Fab 5 Freddy, alongside the Cannabiz Awards. Context Puerto Rico's 75-year history as a pharmaceutical manufacturing hub has shaped a medical cannabis industry built on precise formulations, consistent dosing, and genetics developed specifically for patient needs—a foundation that positions the island favorably as federal rescheduling opens doors to expanded clinical research and international collaboration.

On the labor front, 21 workers at Greenlight Marijuana Dispensary in Joplin, Missouri voted to unionize under UFCW Local 2, citing demands for better job security, consistent scheduling, equitable tip distribution, improved wages, and protection from unilateral corporate changes. The vote reflects broader organizing momentum in Missouri's cannabis sector, where workers at High Profile Cannabis Dispensary in Columbia, Key Dispensary in Springfield, and CBD Kraton—which operates 16 stores across the state—have all voted to join UFCW unions and ratified historic first contracts over the summer. The Joplin action follows allegations last month that a dozen employees at a Springfield Greenlight location were terminated for attempting to unionize, though company representatives claimed the terminations were related to on-the-job cannabis consumption.

In California, data from 1,653 active retail licenses reveals that social equity cannabis holders are outpacing their nonequity counterparts in operational success: 81% of social equity-licensed retailers are active, compared to 76% for nonequity licenses. Money The metric signals that social equity licensing frameworks—designed to center communities disproportionately affected by cannabis prohibition—are delivering measurable economic outcomes and business stability. Separately, Safe Harbor Financial has signed a non-binding term sheet to combine with Opifex Media, creating a Nasdaq-listed diversified holding company that would operate Opifex's creator-economy platform alongside Safe Harbor's established cannabis financial services business. The combination reflects growing financial infrastructure maturation in the cannabis sector as banking and payment solutions become central to industry scaling.

October 26, 2026

Licensed marijuana retailers are driving down local crime rates and boosting community economies, according to analyses released today that underscore the market displacement effect of legal cannabis businesses. Multiple studies show that regulated dispensaries displace unregulated markets, limit youth access, and deliver measurable improvements to local economies—a pattern that has emerged consistently across jurisdictions with established legal frameworks.

Money The broader cannabis industry is navigating significant corporate consolidation, with the Alberta Securities Commission dismissing a legal challenge by Curaleaf Holdings against Aurora Cannabis' at-the-market stock offering program. The regulatory decision marks a win for Aurora in an escalating hostile takeover dispute. Curaleaf launched its unsolicited acquisition bid in August and raised its offer in October to approximately $5 per Aurora share—$1 in cash plus 0.4013 Curaleaf shares. Aurora's board has unanimously rejected the proposal, arguing that it undervalues the company's cash holdings, EU Good Manufacturing Practice-certified facilities, and established international medical operations. The takeover offer is scheduled to expire December 4, though Aurora's special committee continues evaluating alternatives that could provide greater shareholder value.

Consumer confidence in regulated cannabis is strengthening measurably. A Bloomwell survey found that pharmacy cannabis causes four times less stress than purchasing from illegal markets—a gap that reflects the confidence consumers place in licensed retailers and regulated supply chains. Context As more jurisdictions establish legal frameworks, the quality-of-life benefits extend beyond economics into consumer peace of mind and community safety.

Celebrity investment is also flowing into the medical cannabis sector. Rapper Blade Brown has moved into medical cannabis as an investor in Mamedica, signaling continued mainstream legitimacy and capital formation in the therapeutic cannabis space. These high-profile moves reflect a broader pattern: as legal cannabis markets mature and demonstrate tangible economic and public health benefits, investment and entrepreneurial interest expand accordingly.

October 25, 2026

The global cannabis market is on track to nearly double in size over the next five years, with research firm ResearchAndMarkets projecting growth from $45.6 billion in 2025 to $79.3 billion by 2030—an 11.7% compound annual growth rate. That expansion is being driven by three converging forces: the rise of cannabis-derived pharmaceuticals, expansion of legal retail operations, and booming demand for extraction and testing services. Major multi-state operators like Curaleaf, Trulieve, Green Thumb Industries, Verano, and Cresco Labs are positioned as consolidators in an intentionally fragmented market, where regional licensing requirements prevent any single player from achieving national dominance.

Money The earnings picture from the industry's largest retailers reveals a sector maturing toward profitability. Trulieve posted $298 million in Q1 revenue with adjusted EBITDA of $106 million, while Green Thumb Industries—the only major retailer to report a profit last quarter—hit $275.8 million in revenue with $90.5 million in adjusted EBITDA. Curaleaf, the sector's largest by revenue, reported $338.9 million in Q1 sales with $76.7 million in adjusted EBITDA. Across the board, net losses are shrinking dramatically; Trulieve's net loss fell 32% quarter-over-quarter to $23 million. Trulieve's recent listing on the New York Stock Exchange—a historic first for a U.S. cannabis operator—has unlocked institutional access and boosted its stock 28% year-to-date, signaling investor confidence in a maturing business model.

Virginia's legislature just passed bills to legalize adult-use cannabis sales, ending a five-year gap since the state legalized home cultivation. The state's five existing medical licensees can transition to adult-use operations by November 2026 under the House version, or January 2027 under the Senate version, with one-time transition fees between $5 million and $15 million. Meanwhile, New York is exploring an unusual retail strategy: allowing liquor stores to sell low-THC cannabis beverages through a structured permit system, a move designed to expand legal access while undercutting the illicit market. These regulatory expansions are unlocking capital for operators and ancillary businesses like AFC Gamma, a commercial mortgage REIT now deploying $10 million to $100 million loans across cannabis operators in 15 states.

The cannabis sector faces structural headwinds that investors are watching closely. Section 280E, a 1982 tax rule that prohibits cannabis companies from deducting ordinary business expenses, artificially inflates effective tax rates and drains cash flow—though federal rescheduling could change this. Wholesale price compression in states with mature markets like California and Colorado is eroding retail and wholesale margins across the industry, forcing operators to defend profitability through scale and efficiency. Yet the regulated market alone is expected to reach $43 billion by 2030, more than double today's $29.1 billion, creating a clear mathematical advantage for companies operating legally over the unregulated illicit market that generates no tax revenue and offers no consumer protections.

Context Cannabis operators are now filing quarterly earnings with the SEC and trading on major exchanges, subject to the same corporate governance and financial disclosure rules as alcohol producers, pharmaceutical companies, and every other legal industry. Yet cannabis companies pay federal income taxes on gross revenue—not net profit—while being forbidden from deducting basic business expenses, a tax structure applied to almost no other legal sector. What happens when that contradiction finally resolves?

October 24, 2026

The global cannabis market is on track to nearly double in size by 2030, with valuations climbing from $45.6 billion in 2025 to $79.3 billion by decade's end—a compound annual growth rate of 11.7 percent. The industry's fragmented competitive landscape, dominated by multi-state operators like Curaleaf, Trulieve, Green Thumb Industries, Verano, Cresco Labs, and Tilray, is consolidating around winners who can scale profitably. Money In the most recent earnings season, Curaleaf led in net revenue at $338.9 million for Q1, while Trulieve posted $298 million and Green Thumb reported $275.8 million—with Green Thumb notably becoming the only major retailer to post a profit in the quarter. Across the board, net losses are shrinking, with Trulieve cutting losses by 32 percent sequentially and Curaleaf's adjusted EBITDA climbing marginally despite seasonal pressure. The message from financial markets is clear: the largest operators are moving toward sustainable profitability even as competition intensifies.

Regulatory tailwinds are accelerating market expansion at both state and federal levels. Virginia's Democratic-controlled legislature passed bills to legalize adult-use cannabis sales nearly five years after decriminalizing possession, potentially allowing the state's five medical cannabis operators to transition to recreational sales by year-end 2026 or early 2027 under a one-time licensing fee. In New York, lawmakers filed companion bills allowing liquor stores to sell low-THC cannabis beverages through a structured permit system, explicitly designed to expand legal access and reduce illicit market activity. Meanwhile, New York cannabis industry associations are pushing the state to absorb the cost of seed-to-sale tracking systems rather than shifting those expenses to operators already competing with an unregulated illicit market that pays nothing. Context As the legal framework expands and enforcement tightens, why do licensed operators still face disadvantages against illegal competitors operating without licensing fees, compliance staff, or tax obligations?

Money Financing infrastructure is maturing alongside the industry. AFC Gamma, a commercial mortgage REIT, expanded its loan portfolio to 15 states in 2025, deploying $10-100 million facilities to state-licensed operators and capitalizing on reduced banking barriers following federal rescheduling discussions. Curaleaf recently closed a $500 million debt offering at 11.5 percent interest, signaling continued access to capital despite analyst headwinds—Jefferies trimmed revenue expectations for Curaleaf, Trulieve, Cronos, and Canopy Growth, though the firm maintained its ratings intact. ETFs like the AdvisorShares Pure US Cannabis ETF (YOLO) are tracking the sector with top holdings in Curaleaf and Green Thumb, offering retail investors diversified exposure to a $57 billion domestic market.

The competitive pressure is real. Verano's Q1 revenues dropped 7 percent sequentially and 3 percent annually to $221 million, a decline the company attributed directly to intensified competition in New Jersey. Yet even as pricing pressure mounts, the industry remains remarkably fragmented—no single operator controls more than a small percentage of the market, leaving substantial consolidation runway for acquisitive leaders. Trulieve's 2021 acquisition of Harvest Health created a combined entity with 149 dispensaries across 11 states and an annual revenue run rate exceeding $1.2 billion, establishing a playbook for scale that competitors are now following. The data suggests winners will be companies that can expand state-by-state within federal banking and licensing constraints, manage costs amid competition, and position for the moment when federal rescheduling removes the final structural disadvantages that currently plague the sector.